High-Dose Interferon-α2b for Re-treatment of Nonresponders or Relapsing Patients with Chronic Hepatitis C: A Controlled Randomized Trial

Digestive Diseases and Sciences

Volumn 41, Issue 1, 1996, Pages 149-154

  Bonkovsky, Herbert L ^a   Clifford, Bernard D ^a   Smith, Lynda J ^a   Allan, Carol ^a   Banner, Barbara ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Adverse side effects; Chronic hepatitis; Hepatitis C; Interferon therapy

Indexed keywords

ALPHA2B INTERFERON; ENDOGENOUS COMPOUND;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; CHILL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FATIGUE; FEVER; HEADACHE; HEPATITIS C; HUMAN; MYALGIA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ALANINE TRANSAMINASE; CHRONIC DISEASE; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; MALE; RECURRENCE;

EID: 0030062450     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02208597     Document Type: Article

References (31)

1. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 332:1463-1466, 1995
2. van der Poel CL, Cuypers HT, Reesink HW: Hepatitis C six years on. Lancet 344:1475-1479, 1995
3. Bhandari BN, Wright TL: Hepatitis C: An overview. Annu Rev Med 46:309-317, 1995
4. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W: Treatment of chronic hepatitis C with recombinant interferon alpha. A multi-center, randomized controlled trial. N Engl J Med 321:1501-1506, 1989
5. Shindo M, DiBisceglie AM, Hoofnagle JH: Long-term follow-up of patients with chronic hepatitis C treatment with α-interferon. Hepatology 15:1013-1016, 1992
6. Tong MJ, Blatt LM, Klein M, Manyak C, Poulakos J, Sayadzadeh K: Long-term follow-up of chronic hepatitis C virus infected patients treated with consensus interferon. Gastroenterology 108: A1188, 1995
7. Salch MG, Tibbs CJ, Koskinas J, Pereira LMMB, Bomford AB, Portmann BC, McFarlane IG, Williams R: Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 20:1399-1404, 1994
8. Mahancy K, Tedeschi V, Maertcns G, DiBisceglie AM, Vergalla J, Hoofnagle JH, Sallie R: Genotyping analysis of hepatitic C virus in American patients. Hepatology 20:1405-1411, 1994
9. Clifford BD, Smith L, Allan C, Bonkovsky HL: High dose interferon α-2b for retreatment of patients with chronic HCV: A pilot study. Gastroenterology 108:A1050, 1995
10. Tygstrup N: The galactose elimination capacity in control subjects and in patients with cirrhosis of the liver. Acta Med Scand 175:281-289, 1964
11. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL: A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 8:232-238, 1995
12. Knodell RG, Ishak KG, Black WC: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435, 1981
13. Marriott E, Quiroga JA, Carreno V: Retreatment of chronic hepatitis C with interferon-α. J Infect Dis 166:1200-1201, 1992
14. Ferenci P, Stauber R, Propst A, Fiedler R, Gschwanter M, Schutze K, Judmaier G, Krejs GJ, Gangl A: Dose increase augments the response rate of interferon-α in chronic hepatitis C. Gastroenterology 108:A1064, 1995
15. Gerkin G, Teuber G, Goergen B, Meyer Zum-Buschenfelde KH: Interferon-alpha retreatment in chronic hepatitis C. J Hepatol 225:118-121, 1995
16. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP: Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 109:156-165, 1995
17. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S: A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 89:2151-2156, 1994
18. Pozzato G, Moretti M, Saveria-Croce L, Sasso F, Kaneko S, Unoura M, Kobayashi K, Crovatto M, Santini G, Tiribelli C: Interferon therapy in chronic hepatitis C virus: Evidence of different outcomes with respect to different viral strains. J Med Virol 45:445-450, 1995
19. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrams G, Sonnerborg A, Wejstal R, Yun Z-B, Weiland O: High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology 19:280-285, 1994
20. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC, Multi-Center Study Group: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457-1462, 1995
21. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS: Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 20:410-415, 1994
22. Olynyk J, Reddy R, DiBisceglie AM, Jeffers L, Parker TI, Radick TL, Schiff ER, Bacon BR: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 108:1104-1109, 1995
23. Barton AL, Banner BF, Cable EE, Bonkovsky HL: Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 103:419-424, 1995
24. Bukh J, Miller RH, Purcell RH: Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41-63, 1995
25. Terrault N, Wright T: Interferon and hepatitis C. N Engl J Med 332:1509-1511, 1995
26. Carreno V, Tapia L, Ryff J-C, Quiroga JA, Castillo I: Treatment of chronic hepatitis C by continuous subcutaneous infusion of interferon-alpha. J Med Virol 37:215-219, 1992
27. Antonelli G, Currenti M, Turizziani O, Dianzani F: Neutralizing antibodies to interferon: Relative frequency in patients treated with different interferon preparations. J Infect Dis 163:882-885, 1991
28. Rubin RB, Barton AL, Banner BF, Bonkovsky HL: Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 13:223-238, 1995
29. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL: A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 8:232-238, 1995
30. Bacon BR, Rebholz AE, Fried MW, DiBisceglie AM: Effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-a. Hepatology 18:150A, 1993
31. Van Thiel DH, Friedlander L, Mallory P, Faginoli S, Wright HI, Gasbarini A, Caraceni P: Re-treatment of hepatitis C interferon non-response with larger doses of interferon with and without phlebotomy. Gastroenterology 106:A1002, 1994